ITOC4 – 2017

ITOC4-Banner-695x90-201608 DEF

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) had the great pleasure to welcoming you to the 4th Immunotherapy of Cancer Conference (ITOC4) – the leading international conference providing a global platform in Europe for translational research in the field of immuno-oncology.

The fourth edition (ITOC4) took place on Prague, Czech Republic, from 20 to 22 March 2017, aiming at providing a forum for all professionals working in immunotherapy to discuss early clinical drug development and address the unique challenges of translational research. ITOC4 particularly addressed preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals and the pharmaceutical industry.


Have a look at the conference pictures: Google photos


4th Immunotherapy of Cancer Conference (ITOC4), 20-22 March 2017, Prague, Czech Republic – Abstract Book
Journal for ImmunoTherapy of Cancer 2017 5 (Suppl 1):12, 20 March 2017


The ITOC4 Organising Committee wishes to gratefully acknowledge the Scientific Committee and the sponsors for supporting the 4th Immunotherapy of Cancer Conference.


The conference has been granted 12 European CME credits by the European Accreditation Council for Continuing Medical Education (EACCME).


GZ0A1790A lifetime achievement award has been assigned to Thierry Boon, Belgium (Ph.D., Brussels Branch of the Ludwig Institute for Cancer Research)

With the nomination of Professor Boon the ITOC Lifetime Award goes to one of the most renowned researchers in the field of anti-cancer vaccines.


CDDF wishes to congratulate the four winners of the ITOC4 poster awards (awards kindly sponsored by the Munich Tumor Center):

1st Prize:
Célia Jacoberger-Foissac
from the Laboratory of Conception and Application of Bioactives Molecules, Illkirch-Graffenstaden
for the poster “Development of a novel immunotherapy with Toll-like and Nod-like receptors synergy for targeted cancer therapy”

2nd Prize:GZ0A1718
Johannes Laengle
from the Medical University of Vienna
for the poster “GBP1 expression in colorectal cancer liver metastasis associates with increased CD8+ lymphocyte invasion and confers better prognosis”

3rd Prizes:
Felicitas Rataj
from the Klinikum der Universität München
for the poster “Preclinical characterization of a PD-1-CD28 fusion receptor for T cell-based immunotherapy of Non- Hodgkin Lymphoma”

& Michael Ruzicka
from the Ludwig-Maximilians-Universität München
for the poster “Immunotherapy targeting RIG-I in a mouse model of acute myeloid leukemia”


Have a look at the conference pictures: Google photos


View or download the PDF programme

The scientific programme was completed with:

Two sponsored satellite symposia:

  • ‘Cross-Disciplinary Insights and Emerging Tools of the Trade for Immuno-Oncology’ – Bristol-Meyers Squibb
  • ‘Treatment of Immune Excluded and Immune Desert Tumors’ – Roche

Poster sessions which tackled topics suchas:

Preclinical models, Tumor Immunity and Microenvironment, Therapeutic Modulation and Monitoring of Immune Response, Combination Therapy, Anti-cancer Vaccines, Adoptive Cell Therapy.

To have access to the conference presentations, please contact CDDF headquarters:


Join the discussion on Twitter by using #ITOC4 !